News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Compugen Ltd. (CGEN) Discloses Novel Troponin Variant for Identification of Cardiac Muscle Injury, Receipt of Patent for the Molecule and Collaboration with Biosite Incorporated (BSTE)


4/1/2008 9:14:56 AM

TEL AVIV, Israel--(BUSINESS WIRE)--Compugen Ltd. (NASDAQ:CGEN - News) disclosed today the discovery and experimental verification of CGEN-144, a novel variant of Troponin I biomarker, and the signing of a research and license option agreement with Biosite, Inc. Compugen also announced that a patent for this biomarker has been granted by the US Patent and Trademark Office.

Read at press release


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES